company background image
APC

Advanced Proteome Therapeutics TSXV:APC Stock Report

Last Price

CA$0.14

Market Cap

CA$5.6m

7D

7.7%

1Y

-53.3%

Updated

15 Aug, 2022

Data

Company Financials
APC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health0/6
Dividends0/6

APC Stock Overview

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States.

Advanced Proteome Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Advanced Proteome Therapeutics
Historical stock prices
Current Share PriceCA$0.14
52 Week HighCA$0.34
52 Week LowCA$0.085
Beta1.03
1 Month Change16.67%
3 Month Change27.27%
1 Year Change-53.33%
3 Year Change21.74%
5 Year Change-74.54%
Change since IPO-96.32%

Recent News & Updates

Shareholder Returns

APCCA BiotechsCA Market
7D7.7%-3.5%2.5%
1Y-53.3%13.7%1.0%

Return vs Industry: APC underperformed the Canadian Biotechs industry which returned 11.1% over the past year.

Return vs Market: APC underperformed the Canadian Market which returned 0.7% over the past year.

Price Volatility

Is APC's price volatile compared to industry and market?
APC volatility
APC Average Weekly Movement42.7%
Biotechs Industry Average Movement13.0%
Market Average Movement10.6%
10% most volatile stocks in CA Market18.9%
10% least volatile stocks in CA Market4.3%

Stable Share Price: APC is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 43% a week.

Volatility Over Time: APC's weekly volatility has increased from 28% to 43% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aPaul John Woodwardhttps://www.advancedproteome.com

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation.

Advanced Proteome Therapeutics Fundamentals Summary

How do Advanced Proteome Therapeutics's earnings and revenue compare to its market cap?
APC fundamental statistics
Market CapUS$4.31m
Earnings (TTM)US$986.58k
Revenue (TTM)n/a

4.4x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
APC income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other Expenses-US$986.58k
EarningsUS$986.58k

Last Reported Earnings

Apr 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.025
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-68.4%

How did APC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is APC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for APC?

Other financial metrics that can be useful for relative valuation.

APC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-2.9x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does APC's PE Ratio compare to its peers?

APC PE Ratio vs Peers
The above table shows the PE ratio for APC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average12.9x
MPH Medicure
13.8xn/aCA$11.1m
IBT IBEX Technologies
7.6xn/aCA$10.9m
WLLW Willow Biosciences
6.8xn/aCA$14.8m
MBX Microbix Biosystems
23.6x29.4%CA$71.4m
APC Advanced Proteome Therapeutics
4.4xn/aCA$5.6m

Price-To-Earnings vs Peers: APC is good value based on its Price-To-Earnings Ratio (4.4x) compared to the peer average (12.9x).


Price to Earnings Ratio vs Industry

How does APC's PE Ratio compare vs other companies in the North American Biotechs Industry?

Price-To-Earnings vs Industry: APC is good value based on its Price-To-Earnings Ratio (4.4x) compared to the North American Biotechs industry average (15.8x)


Price to Earnings Ratio vs Fair Ratio

What is APC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

APC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio4.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate APC's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of APC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate APC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate APC's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Advanced Proteome Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


32.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Advanced Proteome Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of APC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Advanced Proteome Therapeutics competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Advanced Proteome Therapeutics performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


4.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: APC has high quality earnings.

Growing Profit Margin: APC became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: APC has become profitable over the past 5 years, growing earnings by 4.2% per year.

Accelerating Growth: APC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: APC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: APC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is Advanced Proteome Therapeutics's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: APC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: APC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: APC has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: APC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Debt Coverage: APC's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if APC's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies

Dividend

What is Advanced Proteome Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate APC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as APC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

Paul John Woodward (60 yo)

3.67yrs

Tenure

US$70,000

Compensation

Mr. Paul John Courtney Woodward has been Chief Financial Officer and Director at Railtown AI Technologies Inc. since August 18, 2016 and served as its President and Chief Executive Officer from August 18,...


CEO Compensation Analysis

Compensation vs Market: Paul John's total compensation ($USD70.00K) is below average for companies of similar size in the Canadian market ($USD186.79K).

Compensation vs Earnings: Paul John's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: APC's management team is considered experienced (3.7 years average tenure).


Board Members

Experienced Board: APC's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.1%.


Top Shareholders

Company Information

Advanced Proteome Therapeutics Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Advanced Proteome Therapeutics Corporation
  • Ticker: APC
  • Exchange: TSXV
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$5.555m
  • Shares outstanding: 39.68m
  • Website: https://www.advancedproteome.com

Location

  • Advanced Proteome Therapeutics Corporation
  • 8337 Eastlake Drive
  • Suite 104
  • Burnaby
  • British Columbia
  • V5A 4W2
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/15 00:00
End of Day Share Price2022/08/15 00:00
Earnings2022/04/30
Annual Earnings2021/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.